Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A KOLLER

Showing results (281-290 of 287) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 287 results.
Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Cell Stem Cell|October 30, 2012
Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome systemShannon M Buckley, Beatriz Aranda-Orgilles, Alexandros Strikoudis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Journal of Internal Medicine|January 16, 2021
Association of mitochondrial DNA copy number with metabolic syndrome and type 2 diabetes in 14 176 individualsF Fazzini, C Lamina, A Raftopoulou, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Pageof 29

Showing results (281-290 of 287) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 287 results.
Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemiaM Beran, E Estey, S O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemiasFrancis J Giles, Stefan Faderl, Deborah A Thomas, et al.
Cell Stem Cell|October 30, 2012
Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome systemShannon M Buckley, Beatriz Aranda-Orgilles, Alexandros Strikoudis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Journal of Internal Medicine|January 16, 2021
Association of mitochondrial DNA copy number with metabolic syndrome and type 2 diabetes in 14 176 individualsF Fazzini, C Lamina, A Raftopoulou, et al.
Blood|February 25, 2006
Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
Pageof 29